Sickle cell anemia (SCA), a genetic disorder affecting 0.2% of American blacks, results in severe morbidity and early mortality. Although the specific mutation that causes this disease was described more that thirty years ago, no clearly effective therapy for SCA exists. Recently, dramatic advances have been made in gene targeting and gene transfer techniques, as well as in understanding the mechanisms regulating human gene expression. Manipulation of the human beta-globin locus has now become a plausible therapeutic option for SCA, but will require: 1) reliable animal models, 2) efficient techniques for gene targeting and gene transfer in mammalian stem cells, and 3) a comprehensive understanding of the mechanisms that control tissue-and developmental stage-specific expression of the human beta-globin gene family. Our goal is to more precisely identify the regulatory sequences in the beta-globin locus and to define their functional role during ontogeny. It has not been possible to study the physiological role of cis-acting sequences within the intact human beta-globin region (90 kb) due to the insert size limitations of plasmid (10 kb) and cosmid (40 kb) vectors. However, the recently developed method for cloning genomic fragments of several hundred kb or more into yeast artificial chromosomes (YACs), has now made it feasible to isolate large genetic loci such as the B-globin locus. We will combine the advantages of YAC technology with gene transfer methods, in order to introduce YACs containing the beta-globin gene locus into murine cell lines and transgenic mice. We have extensively characterized two YACs containing the beta-globin gene family including 5' and 3' flanking regions in a single contiguous insert. Using these YACs, we will adapt methods for reliably introducing high molecular weight DNA into cells, while preserving the genomic structure of the fragments after their integration into host chromatin. We will assess the relative advantages of different transfection procedures using murine erythroleukemia cells or embryonic stem (ES) cells, or the microinjection of oocytes for this purpose. Once we have produced cell lines carrying the entire human Beta-globin gene locus, we will use quantitative RNA analysis to study the expression of members of the gene family. We will use homology-directed recombination in yeast to generate mutations of potential regulatory regions. YACs containing these mutations will be transferred into mice or cell lines using the procedures we have developed. The effect of these mutations on tissue and developmental stage specific expression will be analyzed. We believe this work will provide a model system for better understanding the regulation of the human beta-globin locus during ontogeny. Furthermore, the development of transgenic mice and ES cell lines carrying the entire human beta- globin gene locus will allow pre-clinical testing of new pharmacologic agents as well as of gene transfer and targeting procedures, as potential treatments for SCA.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Comprehensive Center (P60)
Project #
5P60HL020985-18
Application #
3736167
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
18
Fiscal Year
1995
Total Cost
Indirect Cost
Name
University of California San Francisco
Department
Type
DUNS #
073133571
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Goodman, Jessica; Hassell, Kathryn; Irwin, David et al. (2014) The splenic syndrome in individuals with sickle cell trait. High Alt Med Biol 15:468-71
James, Ellen Butensky; Vreman, Hendrik J; Wong, Ronald J et al. (2010) Elevated exhaled carbon monoxide concentration in hemoglobinopathies and its relation to red blood cell transfusion therapy. Pediatr Hematol Oncol 27:112-21
Jenkins, Zandra A; Hagar, Ward; Bowlus, Christopher L et al. (2007) Iron homeostasis during transfusional iron overload in beta-thalassemia and sickle cell disease: changes in iron regulatory protein, hepcidin, and ferritin expression. Pediatr Hematol Oncol 24:237-43
Styles, Lori A; Abboud, Miguel; Larkin, Sandra et al. (2007) Transfusion prevents acute chest syndrome predicted by elevated secretory phospholipase A2. Br J Haematol 136:343-4
Kuypers, Frans A; Larkin, Sandra K; Emeis, Jef J et al. (2007) Interaction of an annexin V homodimer (Diannexin) with phosphatidylserine on cell surfaces and consequent antithrombotic activity. Thromb Haemost 97:478-86
Neumayr, Lynne D; Aguilar, Christine; Earles, Ann N et al. (2006) Physical therapy alone compared with core decompression and physical therapy for femoral head osteonecrosis in sickle cell disease. Results of a multicenter study at a mean of three years after treatment. J Bone Joint Surg Am 88:2573-82
Wilson, Leslie S; Moskowitz, Judith Tedlie; Acree, Michael et al. (2005) The economic burden of home care for children with HIV and other chronic illnesses. Am J Public Health 95:1445-52
Vichinsky, Elliott; Butensky, Ellen; Fung, Ellen et al. (2005) Comparison of organ dysfunction in transfused patients with SCD or beta thalassemia. Am J Hematol 80:70-4
Pakbaz, Zahra; Fischer, Roland; Treadwell, Marsha et al. (2005) A simple model to assess and improve adherence to iron chelation therapy with deferoxamine in patients with thalassemia. Ann N Y Acad Sci 1054:486-91
Fricke, Britta; Jarvis, Helen G; Reid, Cecil D L et al. (2004) Four new cases of stomatin-deficient hereditary stomatocytosis syndrome: association of the stomatin-deficient cryohydrocytosis variant with neurological dysfunction. Br J Haematol 125:796-803

Showing the most recent 10 out of 207 publications